Neurologia (Barcelona, Spain) · 2004
[Influence of botulinum toxin treatment on previous primary headaches in patients with cranio-cervical dystonia].
Клиническое исследованиеАннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pascual J
Аннотация
INTRODUCTION: Preliminary data suggest some beneficial effects of botulinum toxin type A (BT-A) on primary headaches.
OBJECTIVE: To analyze the subjective influence of BT-A on previous primary headaches of those patients receiving this treatment due to a variety of cranio-cervical dystonia (CD).
PATIENTS AND METHODS: All patients receiving BT-A due to CD were interviewed with an ad hoc questionnaire on the presence or not of headaches prior to BT treatment. Diagnosis and subjective effects of BT-A on these previous headaches were recorded.
RESULTS: Thirty-eight patients (28 women) were interviewed; 21 (19 women) reported a history of previous primary headache (12 migraine, 10 tension-type headache). Nine (41 %) reported sustained response ( > 50 % reduction in headache frequency) since the beginning of BT-A treatment. Patients with cervical dystonia or those receiving high doses ( > 50 U) showed the best responses. Age, gender, pain location, duration of BT-A treatment and headache diagnosis did not seem to correlate with response.
CONCLUSIONS: BT-A seems to have sustained beneficial effect on primary headaches of some patients with CD, especially at doses higher than 50 U and in patients with the diagnosis of spasmodic torticollis.
OBJECTIVE: To analyze the subjective influence of BT-A on previous primary headaches of those patients receiving this treatment due to a variety of cranio-cervical dystonia (CD).
PATIENTS AND METHODS: All patients receiving BT-A due to CD were interviewed with an ad hoc questionnaire on the presence or not of headaches prior to BT treatment. Diagnosis and subjective effects of BT-A on these previous headaches were recorded.
RESULTS: Thirty-eight patients (28 women) were interviewed; 21 (19 women) reported a history of previous primary headache (12 migraine, 10 tension-type headache). Nine (41 %) reported sustained response ( > 50 % reduction in headache frequency) since the beginning of BT-A treatment. Patients with cervical dystonia or those receiving high doses ( > 50 U) showed the best responses. Age, gender, pain location, duration of BT-A treatment and headache diagnosis did not seem to correlate with response.
CONCLUSIONS: BT-A seems to have sustained beneficial effect on primary headaches of some patients with CD, especially at doses higher than 50 U and in patients with the diagnosis of spasmodic torticollis.